

FOR IMMEDIATE RELEASE

For more information, contact:

Kevin M. Smith
President & CEO
CID4
kevin.smith@cid4.com
(720) 859-4043

Colorado Institute for Drug, Device and Diagnostic Development Sets July 2nd as Submission Due Date for New Project Consideration

The Colorado Institute for Drug, Device and Diagnostic Development (CID4) is seeking its next Portfolio Company, and has set Monday July 2nd as the cut-off for submitting material to CID4.com for consideration.

Aurora, CO June 13, 2012 – The Colorado Institute for Drug, Device and Diagnostic Development (CID4), a 501(c)(3) not-for-profit entity focused on advancing the Colorado life science ecosystem through company creation and job growth, is seeking its next Portfolio Company. A review date of Monday July 2nd has been selected as the cut-off for submitting material to CID4.com for consideration.

CID4 recently launched a new website where business plans are submitted online on a rolling basis. The new CID4 Innovation Database is proving to be a powerful tool, enabling industry partners and investors from all over world to reach into the technology-rich Colorado life science ecosystem. Providing an efficient, single point of entry, the database has been well received by investors and Colorado entrepreneurs. Business plans that had been uploaded to the CID4 Innovation Database have been presented at numerous premiere partnering and investor conferences such as C21 BioVentures, BIO, and BioPartnering North America.

Those who submit their content by July 2nd will be considered for review by management and the CID4 Technical and Business Advisory Committee (TBAC). A use-of-proceeds for up to \$150,000 should be included with the submission packet. For details about the project selection process and where to submit materials visit <http://CID4.com>. Rolling submissions received following the July 2nd cut-off will be considered in the next project evaluation session, to take place in 2013.

“We look forward to this next evaluation cycle and are excited to bring new innovations to our TBAC and Board of Directors,” said Kevin M. Smith, President and Chief Executive Officer of CID4. “Our first five projects have achieved important milestones in their drive to reach the market. The management and financial resources deployed by CID4 have had a material and measurable impact on their successes to date and we look forward to doing more.”

FOR IMMEDIATE RELEASE

CID4 has committed over \$1.4 million to its first five projects, which have created over 30 direct jobs and raised an additional \$3 million of investment capital. CID4 is delivering on its mission of Economic Development through Innovation Advancement.

About the Colorado Institute for Drug, Device and Diagnostic Development

Founded in 2009, the Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)(3) not-for-profit charitable organization whose mission is to advance the Colorado bioscience ecosystem through company creation and job growth. Active business management and capital work in tandem to help bridge the gap between discovery and product development. CID4 works to identify, fund and actively manage emerging life science technologies. This aim is achieved via an ongoing technology solicitation process augmented by additional deal flow sourcing through networked relationships. Active due diligence is provided by CID4 management in consultation with members of the CID4 Technical and Business Advisory Committee. For more information visit <http://CID4.com>.

###